OR WAIT null SECS
March 25, 2015
Emergent BioSolutions announced FDA approval of Anthrasil, an inhalable treatment that targets Anthrax toxins, as well as a contract with BARDA to develop NuThrax, an anthrax vaccine candidate.
March 23, 2015
Guidance provides labeling standards and an implementation guide for electronic submission of lot distribution reports.
The company’s new corporate name will be simply Biogen.
March 18, 2015
The new flow sensors, BioPAT Flow, enable precise, reproducible data to be collected on flow rates and mass balances without coming in contact with the medium during measurement.
WuXi's new facility in Philadelphia will manufacture CAR T-cell therapies and other cancer immunotherapies.
March 17, 2015
Kite Pharma announced that it acquired T-Cell Factory B.V. in an effort to strengthen its T-cell portfolio.
March 16, 2015
Valeant announced that it would increase its original acquisition agreement with Salix to approximately $15.8 billion.
Remsima has demonstrated comparability to the reference product, Remicade, in terms of safety, efficacy, and quality.
March 13, 2015
McNeil-PPC pleads guilty in connection with adulterated infants' and children's over-the-counter liquid medications.
The company will build an R&D team to find promising drug targets with genetic information submitted by customers in its database.